除了减肥:额外的好处可以指导选择抗肥胖药物。

IF 9.5 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Valeria Guglielmi, Silvia Bettini, Paolo Sbraccia, Luca Busetto, Massimo Pellegrini, Volkan Yumuk, Anna Maria Colao, Marwan El Ghoch, Giovanna Muscogiuri
{"title":"除了减肥:额外的好处可以指导选择抗肥胖药物。","authors":"Valeria Guglielmi,&nbsp;Silvia Bettini,&nbsp;Paolo Sbraccia,&nbsp;Luca Busetto,&nbsp;Massimo Pellegrini,&nbsp;Volkan Yumuk,&nbsp;Anna Maria Colao,&nbsp;Marwan El Ghoch,&nbsp;Giovanna Muscogiuri","doi":"10.1007/s13679-023-00502-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.</p><p><strong>Recent findings: </strong>Obesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established. The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.</p>","PeriodicalId":10846,"journal":{"name":"Current Obesity Reports","volume":null,"pages":null},"PeriodicalIF":9.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250472/pdf/","citationCount":"1","resultStr":"{\"title\":\"Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.\",\"authors\":\"Valeria Guglielmi,&nbsp;Silvia Bettini,&nbsp;Paolo Sbraccia,&nbsp;Luca Busetto,&nbsp;Massimo Pellegrini,&nbsp;Volkan Yumuk,&nbsp;Anna Maria Colao,&nbsp;Marwan El Ghoch,&nbsp;Giovanna Muscogiuri\",\"doi\":\"10.1007/s13679-023-00502-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>To highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.</p><p><strong>Recent findings: </strong>Obesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established. The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.</p>\",\"PeriodicalId\":10846,\"journal\":{\"name\":\"Current Obesity Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.5000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250472/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Obesity Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13679-023-00502-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Obesity Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13679-023-00502-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 1

摘要

综述的目的:强调已批准和即将推出的集中作用抗肥胖药物的额外益处,不仅关注最常见的代谢和心血管作用,还关注其较少探索的临床益处和缺点,以便为临床医生提供更全面的肥胖药物管理工具。最近的研究发现:肥胖在世界范围内日益普遍,并已成为卫生保健系统和社会面临的挑战。预期寿命缩短和心脏代谢并发症是这种复杂疾病的一些后果。最近对肥胖病理生理学的深入了解已经导致了几个有希望的药理学靶点的发展,因此甚至更有效的药物即将出现。更广泛的治疗方法增加了个性化治疗的机会。这主要有潜力利用长期使用抗肥胖药物来安全、有效和可持续地减肥,并在已经确定的情况下同时解决肥胖并发症/合并症。随着抗肥胖药物可获得性的不断发展,以及它们对肥胖并发症的附加作用的认识不断增加,临床医生将进入精准医疗的新时代。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.

Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.

Purpose of review: To highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.

Recent findings: Obesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established. The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Obesity Reports
Current Obesity Reports Medicine-General Medicine
CiteScore
16.40
自引率
1.10%
发文量
25
期刊介绍: The main objective of Current Obesity Reports is to provide expert review articles on recent advancements in the interdisciplinary field of obesity research. Our aim is to offer clear, insightful, and balanced contributions that will benefit all individuals involved in the treatment and prevention of obesity, as well as related conditions such as cardiovascular diseases, endocrine disorders, gynecological issues, cancer, mental health, respiratory complications, and rheumatological diseases. We strive to redefine the way knowledge is expressed and provide organized content for the benefit of our readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信